摩尔多瓦共和国2023-2024年国家流感疫苗接种规划评估
2023-2024年流感季,摩尔多瓦共和国独立出资供应流感疫苗,于2023年5月至2024年1月开展混合方法评估,共进行157次访谈及13次疫苗接种观察,识别规划优势与不足,提出制定国家免疫策略、扩大成人及孕妇沟通倡导、利用医患信任关系、开展疫苗犹豫操作研究等建议。
要点
- 评估采用混合方法,共157次访谈及13次疫苗接种观察,覆盖国家免疫规划、地区卫生官员、卫生机构、照护者、医务人员、慢性病成人、孕妇及专家。
- 建议制定国家免疫策略,与国家免疫技术咨询组协商确立国家目标。
- 建议扩大免疫沟通与倡导,尤其面向成人和孕妇,并利用医患信任关系鼓励专科医生将接种作为医疗常规。
核心结论
- 摩尔多瓦共和国国家免疫规划受益于数十年经验、内部进步承诺和外部伙伴贡献,评估识别出四个需改进领域并提出相应建议,以进一步加强该国自持的年度流感疫苗接种规划。
研究设计与样本
- 2023年5月至2024年1月开展混合方法评估,共进行157次访谈:国家免疫规划1次、地区卫生官员6次、卫生机构18次、照护者/父母18次、医务人员34次、慢性病成人43次、孕妇19次,另进行13次疫苗接种观察。
- 另对国际组织、保险公司、公共卫生及卫生部高级政府官员和参与COVID-19工作的人员进行5次专家访谈。
主要发现
- 评估识别出四个需改进领域:制定国家免疫策略、扩大免疫沟通与倡导、利用医患信任关系鼓励专科医生将接种作为医疗常规、开展操作研究理解孕妇等人群疫苗犹豫。
- 专题发现强调确保疫苗剂量不晚于9月送达该国的重要性,医务人员报告9月后送达的疫苗难以接种。
关键数值与推荐
- 建议1:制定国家免疫策略,包括与国家免疫技术咨询组(NITAG)协商确立国家目标。
- 建议2:扩大免疫沟通与倡导举措,尤其面向成人和孕妇。
- 建议3:利用可信赖的医患关系,鼓励专科医生将接种作为医疗常规。
- 建议4:开展操作研究,以更好理解孕妇等人群的疫苗犹豫。
临床怎么用
- 原文建议制定国家免疫策略并与国家免疫技术咨询组协商确立国家目标。
- 原文建议扩大免疫沟通与倡导举措,尤其面向成人和孕妇。
- 原文建议利用可信赖的医患关系,鼓励专科医生将疫苗接种作为医疗常规。
- 原文建议开展操作研究以更好理解孕妇等人群的疫苗犹豫。
- 原文强调确保疫苗不晚于9月送达该国,因医务人员报告9月后送达难以接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the 2023-2024 influenza season, the Republic of Moldova, a lower-middle income country seeking accession into the European Union, independently financed their influenza vaccine supply transitioning from external support from the Partnership for International Vaccine Initiatives, a collaboration conceived in 2015. As part of this transition, a mixed-methods evaluation was conducted from May 2023 - January 2024 to identify current strengths and weaknesses of the influenza vaccination program. A total of 157 interviews were conducted: one with the National Immunization Program (NIP), six with district health officers, 18 at health facilities, 18 with caregivers/parents, 34 with healthcare workers, 43 with adults with chronic diseases, 19 with pregnant women, and 13 vaccine observation sessions; further five expert interviews with an international organization, the insurance company, senior government officials in public health and within the ministry of health, and those involved with COVID-19 were conducted. The Republic of Moldova's NIP has benefited from decades of experience, internal commitments to progress, and contributions from external partners. Despite this progress, the evaluation recognized four areas for improvement. Recommendations from the evaluation assessment included: 1) develop a national strategy for immunization, including the establishment of national goals in consultation with the national immunization technical advisory group (NITAG); 2) expand immunization communications and advocacy initiatives, particularly to adults and pregnant individuals; 3) leverage trusted patient-doctor relationships and encourage vaccination as a healthcare norm with physician specialists; and 4) conduct operations research to better understand vaccine hesitancy in populations such as pregnant individuals. Additional thematic findings emphasized the importance of ensuring timely receipt of vaccine doses into the country no later than September, as medical providers reported difficulty administering doses when vaccines were delivered after September. Our findings outline ways to further strengthen the Republic of Moldova's self-sustained annual influenza vaccination program.
引用
- Shen AK, Gutu V, Druc A, et al. An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024. Vaccine. 2024. PMID: 39293299. doi:10.1016/j.vaccine.2024.126322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。